“…In the field of palliative care, reports on the use of TH date back to the 1960s [17,18,19,20]. Several reports on the use of TH with palliative and anti-angiogenic intention for patients with malignant gliomas have been published, which are summarized in table 1[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Most of them, including the most recent studies, failed to meet the expectations of the investigators regarding the efficacy of an alternative anti-angiogenic agent.…”